Study of keynatinib for certain hard-to-treat lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests keynatinib, a new medicine, in people with specific types of lymphoma that have returned or not responded to earlier treatment. It aims to find a safe dose and see whether it can shrink tumors in the brain or elsewhere in the body, depending on the group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign consent and follow the study plan
- Your cancer must match one of these types: PCNSL, CLL/SLL, or mantle cell lymphoma
- You must have measurable tumor spots on CT or MRI (size rules will be checked)
- You must be well enough to tolerate treatment (ECOG performance score 0–2) and expected survival of at least 4 months
- Your blood counts and organ tests (kidneys, liver, clotting) must meet study thresholds
- If you can become pregnant or father a child, you must use effective birth control during the study and after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a targeted therapy called a PI3K inhibitor for people whose T-cell or NK-cell lymphoma has returned or not improved after other treatments. It aims to see if the drug can shrink or control the lymphoma.
This study tests a new drug called CN201 (also known as MK-1045) for people with certain types of B-cell lymphoma that have come back or not responded to previous treatments. The goal is to see if the drug can help shrink or control the cancer.
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This Phase 1/2 study tests an experimental medicine (RNK05047) in people with advanced solid tumors or diffuse large B‑cell lymphoma whose standard treatments haven’t worked or can’t be tolerated. It may help shrink tumors and improve control of the disease, but early-phase trials also focus on safety and dosing.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.